[Erlotinib in the treatment of NSCLC: current and novel prospects from the ASCO 2006].
Longo
Flavia
F
Oncologia Medica, Policlinico Umberto I, Roma.
Giovanni
Mansueto
M
D000230:Adenocarcinoma / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D044466:Asian People; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D002986:Clinical Trials as Topic; D000069347:Erlotinib Hydrochloride; D019317:Evidence-Based Medicine; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D012737:Sex Factors; D012907:Smoking / Q000009:adverse effects; D016019:Survival Analysis
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride